← All trials
NCT04471974
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 7, 2020
- Primary completion
- Dec 31, 2025
- Completion date
- Dec 31, 2025
- First posted
- Jul 15, 2020
- Last posted
- Dec 22, 2020
- Enrollment
- 54
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of California, San FranciscoLead sponsor
- MerckCollaborator
- University of California, San FranciscoOverall official - principal investigator
- University of California, San FranciscoSponsor investigator
- Zenith EpigeneticsCollaborator
- United States ArmyCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.